Emanuel Keller | Head Pharma & Consumer Health

  • /

    Franca Marotta (ALK Switzerland) on Allergy Immunotherapy 

    Allergies are affecting more and more people in their daily lives, often for their entire lives, and frequently starting in…

Allergies are affecting more and more people in their daily lives, often for their entire lives, and frequently starting in childhood. As the number of people affected rises, so do the demands on treatment, education, and medical care. In the Stettler CEO Talk, Franca Marotta, General Manager of ALK Switzerland, discusses current developments in allergology—the medical specialty focused on the research, diagnosis, and treatment of allergies. She also talks about allergy immunotherapy, leadership, and a sustainable corporate culture.

From Gut Feeling to Allergology

Ms. Marotta, you’ve been General Manager of ALK Switzerland for two years and previously headed the company’s marketing department. What originally led you to allergology, and what keeps you in this field today?

The pharmaceutical industry—and the field of allergology in particular—was not a consciously planned career move. I studied Applied Linguistics at the ZHAW and worked as an interpreter. My professional path initially took me through various industries, including the energy sector.

About ten years ago, I had my job interview at ALK and literally “stumbled” into this job: there was a rug on the floor that I actually tripped over. During the interview, my gut feeling told me very clearly that this was the right path for me.

Allergology quickly resonated with me on a personal level. Allergies affect an incredible number of people, often starting as early as childhood. You’re constantly confronted with this reality in your day-to-day work, whether in discussions with doctors or in conversations with colleagues, friends, and acquaintances. This has given me a strong sense of purpose: not only to alleviate symptoms, but also to have a lasting positive impact on the course of the disease and to advocate for this causal treatment method at the FOPH. 

ALK Switzerland: A Market Leader with a Rich Tradition

For readers who aren’t yet familiar with ALK in detail: What does the company stand for, and what sets ALK apart from traditional pharmaceutical companies?

The abbreviation “ALK” stands for Allergologisches Labor Kopenhagen (Copenhagen Allergy Laboratory) and was founded in 1923. For over 100 years, the company has specialized in allergy immunotherapy. ALK is the market leader in the field of allergen-specific immunotherapy both globally and in Switzerland.  
 
The key difference from many traditional pharmaceutical approaches is that we don’t just treat symptoms—we address the root cause. Our goal is to train the immune system over the long term and build lasting tolerance to allergens. Although immunotherapy takes longer than purely symptomatic treatment , it has a lasting impact on the course of the disease. This advantage is particularly evident  in young patients, as children often respond very well to the therapy.


ALK is also the market leader in Switzerland. How does the company differentiate itself from the competition here?

Various dosage forms are used in allergen-specific immunotherapy. ALK offers both sublingual and subcutaneous immunotherapy. While one form consists of tablets or drops placed under the tongue, the other involves injections. This allows therapies to be better tailored to patients’ needs. ALK is part of a foundation whose bylaws stipulate that a certain percentage of annual profits must be invested in clinical trials. Our evidence-based therapies are therefore grounded in current data and adhere to modern standards. This is crucial today. Patients consciously choose therapies whose benefits have been scientifically proven in studies.

Allergy Immunotherapy in a State of Transition

How would you describe the current state of allergology in Switzerland?

We’re seeing a significant increase in demand. More and more people are affected by allergies, and climate change is exacerbating this trend. For example, pollen seasons aren’t just shifting—they’re getting longer. This also extends the period during which those affected suffer from allergy symptoms. At the same time, allergology is increasingly becoming part of primary care. Care is more often provided by family physicians or pediatricians rather than by specialists. This is generally a positive development, but it also brings new challenges.

What exactly are these challenges?

The main challenges are particularly evident in:

– shortages in medical care: too few specialists, excessively long wait times
– a lack of knowledge about allergy immunotherapy among those affected, as well as among general practitioners and pediatricians
– the still insufficient integration of allergology into primary care

Accordingly, there is a need for targeted education, continuing education, and better integration into existing healthcare systems.

Patients today are better informed than they used to be. How is this changing the field of allergology?

What innovations will shape immunotherapy in the coming years?

The development of new dosage forms is a key focus. A milestone was the introduction of sublingual allergy immunotherapy in the early 2000s. In this approach, attenuated allergens in the form of drops or self-dissolving tablets are placed under the tongue daily. This form of allergen-specific immunotherapy gradually acclimates the immune system to the allergen and can alleviate or prevent allergic reactions in the long term. Research is constantly evolving. We view innovation not only as the development of new products, but also as a way to make therapies more suitable for everyday use and easier to administer.

Leadership at ALK Switzerland: Culture, Transparency, and Trust

What leadership approaches have proven effective in your role as General Manager of ALK Switzerland?

It’s important to me to create a work environment characterized by respect, appreciation, and friendly interactions. Employees should feel comfortable and be able to actively contribute without fear of making mistakes or sharing a different perspective.

In my view, three aspects are crucial here:

– an open culture of error, in which mistakes are seen as opportunities to learn

– mutual respect and appreciation in our day-to-day interactions

– transparency in decisions and goals

Transparency, in particular, plays a central role. Employees should understand where we’re headed, what strategic goals are being set at the global level, and how these are being implemented in Switzerland. When people know why decisions are made, they feel included and work with dedication toward shared goals.

How do you view female leadership in the pharmaceutical industry?

Female leadership is a matter close to my heart. At ALK, women are naturally and numerous in leadership positions; diversity is actively embraced.

From my own experience, I’ve never felt disadvantaged. However, that’s just my personal perception. Within my network, I also hear other stories that show there’s still a lot of work to be done. Ultimately, it’s a matter of corporate culture. Values only take effect when they’re actively modeled from the top down. That’s what happens here—from management all the way down to the team. That’s exactly why diversity isn’t just a buzzword—it’s a lived reality.

Where ALK Switzerland Is Headed by 2030

Where should ALK Switzerland be heading in the coming years?

Our goal is clear: By 2030, we aim to reach approximately five million patients worldwide with our state-of-the-art therapies—twice as many as today. We are placing a special focus on pediatric care.
 
At the same time, we’re investing in expanding our team in Switzerland. For me, growth isn’t just about market share—it’s also about helping people grow.

Finally: What advice would you give your 20-year-old self?

Listening to yourself and staying true to yourself is crucial. Uncertainties are part of the process, because at 20, nothing is set in stone yet. The important thing is to trust in your own abilities.
 
The path often only becomes clear as you go along, and looking back, many things fall into place on their own.

Conclusion

The conversation with Franca Marotta shows just how much allergology is changing. Rising numbers of people with allergies and well-informed patients call for sustainable, evidence-based treatment approaches. Allergen-specific immunotherapy addresses the root cause and is becoming increasingly important.